








key: cord-337557-ct43uoir
authors: Guetl, Katharina; Moazedi-Fuerst, Florentine; Rosskopf, Konrad; Brodmann, Marianne; Krause, Robert; Eller, Philipp; Wilhelmer, Patricia; Eisner, Florian; Sareban, Nazanin; Schlenke, Peter; Kessler, Harald H.; Steinmetz, Ivo; Redlberger-Fritz, Monika; Stiasny, Karin; Stradner, Martin
title: SARS-CoV-2 positive virus culture 7 weeks after onset of COVID-19 in an immunocompromised patient suffering from X chromosome-linked agammaglobulinemia
date: 2020-10-27
journal: J Infect
DOI: 10.1016/j.jinf.2020.10.025
sha: 
doc_id: 337557
cord_uid: ct43uoir

nan

) are considered to be without infectious potential beyond day 10 after the onset of symptoms. In contrast, immunocompromised and severe-to-critical patients may have prolonged viral shedding and, thus, may also provide prolonged infectiousness.

Data addressing prolonged viral shedding and potential spread of SARS-CoV-2 are matter of public concern. Whereas isolation precautions as recommended by the United States Centers of Disease Control and Prevention (2) and the European health care authorities (3) are considered to fit for most SARS-CoV-2 infected patients, uncertainty remains in those patients with underlying immunodeficiency. Walsh et al. included a total of 15 relevant studies, but only two of them identified immunosuppressed patients from whom SARS-CoV-2 was isolated for up to 20 days beyond onset of disease. (4, 5) Here, we report SARS-CoV-2 positive viral culture 7 weeks after onset of COVID-19 in a patient with an underlying immunosuppressive disorder, so-called X chromosome-linked agammaglobulinemia (XLA), demonstrating the potential of prolonged SARS-CoV-2 spreading beyond widely accepted isolation precautions.

Our patient had been tested positive for SARS-CoV-2 ribonucleic acid (RNA) by reverse transcription polymerase chain reaction (RT-PCR) from upper respiratory specimen first on March 11 2020. At this point of time, symptoms comprised fever and fatigue. In the patient's medical history, XLA, obstructive respiratory disorder, impaired alveolar diffusion capacity and non-cystic fibrosis bronchiectasis were recorded. Due to worsening of fever, cough and dyspnea, the patient required for hospitalization 16 days after the initial diagnosis of COVID-19. The patient received antibiotic treatment with amoxicillin/clavulanic acid and azithromycin, was switched to piperacillin/tazobactam, followed by moxifloxacin and meropenem. Based on local recommendations valid at this point of time, the patient was treated with hydroxychloroquine and then by an antiretroviral combination of lopinavir/ritonavir. Furthermore, posaconazole was administered for Aspergillus positive sputum culture and intravenous immunoglobulin substitution (IVIG) was performed regarding the absence of endogenous antibody production in underlying XLA. Due to persistent fever up to 40.4°C, progressive respiratory insufficiency and deterioration of laboratory parameters expressing an increasing inflammatory activity, the patient was transmitted to the Intensive Care Unit (ICU) on April 9. Interleukin-6 (IL-6) receptor blockade by tocilizumab and convalescent plasma were administered on April 10. No adverse effects related to this treatment regimen were recorded. The rationale behind this approach was to restrain the inflammatory response by IL-6 blockade and to provide neutralizing COVID-19 immunoglobulins by convalescent plasma. Afterwards, we observed a rapid recovery regarding clinical and laboratory parameters. Ferritin and C-reactive protein (CRP) significantly declined as compared to pretransfusion whereas the lymphocyte count returned to normal. We observed an increase in IL-6 after treatment followed by a fast and almost complete decline within the next days. Body temperature did not exceed a limit of 38°C as compared to measurements of up to 40.4°C pre-transfusion. Oxygen demand decreased resulting in an increase of PaO2/FiO2 ratio (143 before versus 223 after treatment). A chest radiograph showed a significant decline in infiltrative opacities. On April 15, five days after tocilizumab and convalescent plasma administration and five weeks after the initial diagnosis of COVID-19, SARS-CoV-2 RNA was not detectable for the first time. The patient showed progressive clinical recovery, but an alternating course of three negative followed by three positive SARS-CoV-2 RT-PCR results was subsequently observed. Convalescent plasma transfusion was showed 500 copies/mL in transport medium (containing the oropharyngeal swab) and the viral culture was negative. Figure 1 presents an overview by timeline from the initial diagnosis of COVID-19 up until negative viral culture.

In summary, we have to assume that in our patient shedding of infectious SARS-CoV-2 stopped between week 7 and 10 of disease. Our patient suffers from XLA, also known as Bruton's agammaglobulinemia, which is caused by a mutation in Bruton's tyrosine kinase resulting in an inability of endogenous antibody production du to a developmental arrest of pre B cells. 

Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19

Guidance for discharge and ending isolation in the context of widespread community transmission of COVID-19 -first update

Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants

CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation

Virological assessment of hospitalized patients with COVID-2019

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

X-Linked Agammaglobulinaemia: Outcomes in the modern era

A possible role for B cells in COVID-19?: Lesson from patients with Agammaglobulinemia

None to declare.

None to declare.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

